Shares of Immuneering dropped after the oncology company said its Phase 2a trial of a first-line pancreatic cancer treatment saw a 64% survival rate over 12 months. Shares fell 43%, to $4.73, Thursday ...
In this video, Lukas Delasos, DO, discusses updates from the CheckMate 816 trial presented at this year's ASCO Annual Meeting. The newly released findings provided additional survival data on the use ...
Transforming EHR data into image matrices enhances deep learning models' accuracy in predicting 5-year survival in colorectal cancer. The VGG16 model achieved up to 78% accuracy and high specificity, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results